Form 4: VolitionRx CEO Salvatore Butera Receives Equity Compensation, Shares Withheld for Tax Obligations

VolitionRx Ltd.'s CEO of Volition Veterinary, Salvatore Thomas Butera, was awarded 23,377 restricted stock units as compensation, with 11,683 shares subsequently withheld by the company to cover tax obligations.

Summary

• Salvatore Thomas Butera, CEO of Volition Veterinary at VolitionRx Ltd. (VNRX), was awarded 23,377 restricted stock units (RSUs) on June 1, 2025.
• These RSUs were granted under the Issuer's 2015 Stock Incentive Plan in lieu of cash compensation.
• The RSUs will vest in three partial installments: 7,793 units on June 1, 2025; 7,792 units on July 1, 2025; and 7,792 units on August 1, 2025. They are also subject to further time-based vesting in a single installment on August 1, 2025, contingent on continued service.
• On the same date, 11,683 shares of common stock were retained by VolitionRx for cancellation to satisfy tax withholding obligations related to the settlement of 35,783 previously awarded restricted stock units.
• The shares withheld for tax purposes were valued at $0.503 per share, and no shares were sold by the reporting person or VolitionRx in this transaction.
• Following these transactions, Salvatore Thomas Butera directly beneficially owns 314,379 shares of common stock, in addition to 99,350 shares jointly owned with his spouse.

Sentiment

Score: 6

Explanation: The sentiment is moderately positive as it reflects ongoing executive compensation through equity, aligning management interests with shareholders, and is a routine transaction. The tax withholding is a neutral, administrative event.

Positives

• The award of 23,377 restricted stock units (RSUs) to CEO Salvatore Thomas Butera demonstrates continued equity-based compensation, aligning management interests with shareholders.
• The RSUs were granted in lieu of cash compensation, which may help conserve cash for the company.

Negatives

• 11,683 shares were withheld by the company to cover tax obligations, which reduces the number of shares directly held by the CEO from the RSU settlement.

Future Outlook

The document indicates future vesting schedules for restricted stock units on July 1, 2025, and August 1, 2025, contingent on continued service, which implies the company's expectation of the CEO's ongoing tenure.

Industry Context

This Form 4 filing details routine equity compensation and tax withholding for a senior executive, which is a common practice across industries to align executive incentives with shareholder value and manage tax liabilities associated with equity awards. It does not provide broader industry trends or competitive insights.

Related Party Transactions

• The award of 23,377 restricted stock units to Salvatore Thomas Butera, CEO of Volition Veterinary, by VolitionRx Ltd. constitutes a related party transaction as it involves compensation from the company to a key executive.

Stakeholder Impact

• Shareholders: The equity award aligns the CEO's interests with shareholders, as the value of his compensation is tied to the company's stock performance. The withholding of shares for tax purposes is a routine administrative event with minimal direct impact on other shareholders.

Next Steps

• Vesting of 7,792 restricted stock units on July 1, 2025.
• Vesting of 7,792 restricted stock units and further time-based vesting on August 1, 2025.

Key Dates

Keywords

VolitionRx, VNRX, SEC Form 4, Insider Trading, Restricted Stock Units, RSU, Equity Compensation, Tax Withholding, Salvatore Thomas Butera, CEO, Beneficial Ownership, Corporate Governance